Data / Drug companies / Cytochrome P450 2D6 Inhibitor
Cytochrome P450 2D6 Inhibitor drugs: 5 drugs from 10 companies in the FDA NDC directory
Cytochrome P450 2D6 Inhibitor is an FDA established pharmacologic class. The FDA National Drug Code Directory lists 11 products in this class from 10 companies, covering 5 drugs by generic name. The main marketing category is generic drugs (ANDA), and the newest product started marketing on September 16, 2026.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- 10Companies
- 11Products
- 5Drugs by generic name
Drugs in the Cytochrome P450 2D6 Inhibitor class
Ranked by number of companies that list the drug.
| Drug | Products here | Companies listing it |
|---|---|---|
| Dextromethorphan hydrobromide and quinidine sulfate | 4 | 4 |
| Dextromethorphan hydrobromide and quinidine sulphate | 2 | 2 |
| Quinidine gluconate | 2 | 2 |
| Quinidine sulfate tablet | 2 | 1 |
| Quinidine gluonate | 1 | 1 |
Companies with the most products in this class
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Epic Pharma, LLC | 2 | tablet | Generic drugs (ANDA) | December 15, 2021 |
| Avanir Pharmaceuticals, Inc. | 1 | capsule, gelatin coated | New drug applications (NDA) | December 1, 2010 |
| Camber Pharmaceuticals, Inc. | 1 | capsule | Generic drugs (ANDA) | August 28, 2024 |
| Eywa Pharma Inc | 1 | tablet, extended release | Generic drugs (ANDA) | March 20, 2022 |
| Golden State Medical Supply, Inc. | 1 | capsule | Generic drugs (ANDA) | June 3, 2026 |
| Golden State Medical Supply, Inc. | 1 | tablet, extended release | Generic drugs (ANDA) | February 11, 1987 |
| Otsuka America Pharmaceutical, Inc. | 1 | capsule, gelatin coated | New drug applications (NDA) | January 3, 2023 |
| Sun Pharmaceutical Industries, Inc. | 1 | tablet, extended release | Generic drugs (ANDA) | February 10, 1987 |
| Sun Pharmaceutical Industries, Inc. | 1 | capsule | Generic drugs (ANDA) | July 30, 2026 |
| Teva Pharmaceuticals, Inc. | 1 | capsule | Generic drugs (ANDA) | September 16, 2026 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Capsule | 4 | 36.4% |
| Tablet, extended release | 3 | 27.3% |
| Tablet | 2 | 18.2% |
| Capsule, gelatin coated | 2 | 18.2% |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.